Long-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-10-01 DOI:10.4274/dir.2024.242874

Jae Hwan Lee, Jihyung Yoon, Chong-Ho Lee, Kun Yung Kim, Chang Jin Yoon, Minuk Kim, Seul Ki Kim

{"title":"Long-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma.","authors":"Jae Hwan Lee, Jihyung Yoon, Chong-Ho Lee, Kun Yung Kim, Chang Jin Yoon, Minuk Kim, Seul Ki Kim","doi":"10.4274/dir.2024.242874","DOIUrl":null,"url":null,"abstract":"Purpose: Although favorable results have been reported on catheter-directed sclerotherapy (CDS) for ovarian endometrioma, a thorough evaluation of its long-term efficacy is lacking. This study evaluates the long-term efficacy and safety of CDS with 99% ethanol for treatment of ovarian endometrioma.Methods: Between January 2020 and February 2022, data from 33 consecutive patients with symptomatic ovarian endometriomas who underwent CDS were retrospectively evaluated. All patients underwent pre-procedural and 6- and 12-month post-procedural ultrasonography. To assess the effect on ovarian reserve, serum anti-Müllerian hormone (AMH) levels were measured before and after the procedure. Procedure-related complications were also assessed.Results: The mean volume of endometriomas decreased from 80.22 ± 66.43 to 0.73 ± 1.10 mL (P < 0.001), and the mean percentage of volume reduction was 98.99% ± 1.53%. No recurrences were observed during the follow-up period. In patients whose serum AMH levels were monitored for 1 year, no significant change in AMH level before and after CDS was observed (3.07 ± 1.81 vs. 2.72 ± 2.02 ng/mL, P = 0.190). One patient complained of moderate abdominal pain after CDS, which was conservatively managed.Conclusion: CDS remained safe and effective in treating ovarian endometrioma at the 1-year follow-up. Ovarian function after CDS was well preserved.Clinical significance: CDS is a safe and effective treatment option for patients with ovarian endometrioma without compromising ovarian function.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/dir.2024.242874","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Although favorable results have been reported on catheter-directed sclerotherapy (CDS) for ovarian endometrioma, a thorough evaluation of its long-term efficacy is lacking. This study evaluates the long-term efficacy and safety of CDS with 99% ethanol for treatment of ovarian endometrioma.

Methods: Between January 2020 and February 2022, data from 33 consecutive patients with symptomatic ovarian endometriomas who underwent CDS were retrospectively evaluated. All patients underwent pre-procedural and 6- and 12-month post-procedural ultrasonography. To assess the effect on ovarian reserve, serum anti-Müllerian hormone (AMH) levels were measured before and after the procedure. Procedure-related complications were also assessed.

Results: The mean volume of endometriomas decreased from 80.22 ± 66.43 to 0.73 ± 1.10 mL (P < 0.001), and the mean percentage of volume reduction was 98.99% ± 1.53%. No recurrences were observed during the follow-up period. In patients whose serum AMH levels were monitored for 1 year, no significant change in AMH level before and after CDS was observed (3.07 ± 1.81 vs. 2.72 ± 2.02 ng/mL, P = 0.190). One patient complained of moderate abdominal pain after CDS, which was conservatively managed.

Conclusion: CDS remained safe and effective in treating ovarian endometrioma at the 1-year follow-up. Ovarian function after CDS was well preserved.

Clinical significance: CDS is a safe and effective treatment option for patients with ovarian endometrioma without compromising ovarian function.

查看原文本刊更多论文

导管定向硬化疗法治疗卵巢子宫内膜异位症的长期疗效。

目的：虽然导管引导硬化剂注射（CDS）治疗卵巢子宫内膜异位症取得了良好的效果，但缺乏对其长期疗效的全面评估。本研究评估了使用99%乙醇治疗卵巢子宫内膜异位症的长期疗效和安全性：2020年1月至2022年2月期间，对33例连续接受CDS治疗的无症状卵巢子宫内膜异位症患者的数据进行了回顾性评估。所有患者均接受了术前及术后 6 个月和 12 个月的超声波检查。为了评估对卵巢储备的影响，在手术前后测量了血清抗缪勒氏管激素（AMH）水平。此外，还评估了与手术相关的并发症：结果：子宫内膜异位症的平均体积从 80.22 ± 66.43 mL 减少到 0.73 ± 1.10 mL（P < 0.001），体积缩小的平均百分比为 98.99% ± 1.53%。随访期间未发现复发。在对血清AMH水平进行1年监测的患者中，观察到CDS前后AMH水平无明显变化（3.07 ± 1.81 vs. 2.72 ± 2.02 ng/mL，P = 0.190）。一名患者在CDS后主诉中度腹痛，经保守治疗后缓解：结论：CDS治疗卵巢子宫内膜异位症仍然安全有效。临床意义：临床意义：对卵巢子宫内膜异位症患者来说，CDS是一种安全有效的治疗方案，不会损害卵巢功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.